嘉兴和剂药业

Heji Pharma is a clinical-stage biopharmaceutical company based in Jiaxing, China, specializing in the development of novel small molecule drugs for autoimmune and inflammatory diseases. Founded by industry veterans with extensive experience in kinase inhibitor research, the company focuses on creating highly selective therapies that offer better safety and efficacy than existing treatments. Its lead program, HJP-273, is a potent JAK1 inhibitor undergoing Phase 2 clinical evaluation for rheumatoid arthritis and atopic dermatitis. Heji Pharma's pipeline also includes HJP-601, a TYK2 inhibitor, and several discovery-stage programs targeting key pathways in immunology and oncology. The company is backed by prominent venture capital firms and aims to address significant unmet medical needs in the global immunology market.